Resiquimod

N/A

Report date: 2025/06/06 14:53:33
NME

Base Information

Drug NameResiquimod
Drug Alias Name瑞喹莫德R-848VML-600S-28463CD-11301
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionToll like receptor 7 agonistsToll like receptor 8 agonists
TargetsToll like receptor 7Toll like receptor 8
Therapy Area/IndicationsUrinary Bladder NeoplasmsMelanomaLymphoma, T-Cell, Cutaneous
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyFrance
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator Companies3m
China Registration ClassN/A

Develop Information

Active CompaniesSurge Therapeutics Inc
Inactive CompaniesGalderma R&DThe University Of Texas MD Anderson Cancer Center
Active IndicationsUrinary Bladder Neoplasms
Inactive IndicationsMelanomaLymphoma, T-Cell, Cutaneous

Other Information

ATC CodeN/A
Related LinksN/A